Compare AOUT & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AOUT | CGEN |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.1M | 125.3M |
| IPO Year | N/A | 2000 |
| Metric | AOUT | CGEN |
|---|---|---|
| Price | $7.85 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 99.1K | ★ 278.6K |
| Earning Date | 12-09-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $207,348,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.08 | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $6.26 | $1.13 |
| 52 Week High | $17.91 | $2.66 |
| Indicator | AOUT | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.88 | 43.59 |
| Support Level | $7.04 | $1.47 |
| Resistance Level | $8.16 | $1.72 |
| Average True Range (ATR) | 0.37 | 0.09 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 82.12 | 24.01 |
American Outdoor Brands Inc is engaged in the business of providing outdoor products and accessories for hunting, fishing, camping, shooting, and personal security and defense products. The company designs and produces products and accessories, including shooting supplies, rest, vaults, and other related accessories; premium sportsman knives and tools for fishing and hunting; land management tools for hunting preparedness; harvesting products for post-hunt or post-fishing activities; electro-optical devices, including hunting optics, firearm aiming devices, flashlights, and laser grips; reloading, gunsmithing, and firearm cleaning supplies; and survival, camping, and emergency preparedness products.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.